35303-13-0|Kinamycin B|5H-Benzo(b)carbazole-5-carbonitrile, 3-(acetyloxy)-1,2,3,4,6,11-hexahydro- 1,2,4,7-tetrahydroxy-3-methyl-6,11-dioxo-|-范德生物科技公司

Kinamycin B

NMR下载 COA and HPLC MSDS下载
names：
5H-Benzo(b)carbazole-5-carbonitrile, 3-(acetyloxy)-1,2,3,4,6,11-hexahydro- 1,2,4,7-tetrahydroxy-3-methyl-6,11-dioxo-
CAS号：
35303-13-0
MDL Number：
MF(分子式)： C20H16N2O8 MW(分子量)： 412.35
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Kinamycin B
英文别名	Kinamycin B; Kinamycin-B; KinamycinB;
CAS号	35303-13-0
SMILES	N#CN1C(C(C2=C(O)C=CC=C23)=O)=C(C4=C1C(O)C(OC(C)=O)(C)C(O)C4O)C3=O
Inchi	InChI=1S/C20H16N2O8/c1-7(23)30-20(2)18(28)14-12(17(27)19(20)29)11-13(22(14)6-21)16(26)10-8(15(11)25)4-3-5-9(10)24/h3-5,17-19,24,27-29H,1-2H3
InchiKey	VTBQTYQHTVTELM-UHFFFAOYSA-N
分子式 Formula	C20H16N2O8
分子量 Molecular Weight	412.35
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Kinamycin B(CAS:35303-13-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Kinamycin B is an antibacterial agent that is used for anticancer purposes.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Wang B, Ren J, Li L, Guo F, Pan G, Ai G, Aigle B, Fan K, Yang K. Kinamycin biosynthesis employs a conserved pair of oxidases for B-ring contraction. Chem Commun (Camb). 2015 May 25;51(42):8845-8. doi: 10.1039/c5cc01986a. PubMed PMID: 25920893.

[2]Woo CM, Gholap SL, Lu L, Kaneko M, Li Z, Ravikumar PC, Herzon SB. Development of enantioselective synthetic routes to (-)-kinamycin F and (-)-lomaiviticin aglycon. J Am Chem Soc. 2012 Oct 17;134(41):17262-73. doi: 10.1021/ja307497h. Epub 2012 Oct 3. PubMed PMID: 23030272; PubMed Central PMCID: PMC3505684.

[3] Gould SJ, Melville CR, Cone MC, Chen J, Carney JR. Kinamycin Biosynthesis. Synthesis, Isolation, and Incorporation of Stealthin C, an Aminobenzo[b]fluorene. J Org Chem. 1997 Jan 24;62(2):320-324. PubMed PMID: 11671405.

[4] Kumamoto T. [Synthetic studies on kinamycin antibiotics]. Yakugaku Zasshi. 2010 Nov;130(11):1535-41. Review. Japanese. PubMed PMID: 21048414.

[5] Omura S, Nakagawa A, Yamada H, Hata T, Furusaki A. Structures and biological properties of Kinamycin A, B, C, and D. Chem Pharm Bull (Tokyo). 1973 May;21(5):931-40. PubMed PMID: 4727361.

6: Seaton PJ, Gould SJ. New products related to kinamycin from Streptomyces murayamaensis. II. Structures of pre-kinamycin, keto-anhydrokinamycin, and kinamycins E and F. J Antibiot (Tokyo). 1989 Feb;42(2):189-97. PubMed PMID: 2925510.7: Hasinoff BB, Wu X, Yalowich JC, Goodfellow V, Laufer RS, Adedayo O, Dmitrienko GI. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects. Anticancer Drugs. 2006 Aug;17(7):825-37. PubMed PMID: 16926632.8: Colis LC, Woo CM, Hegan DC, Li Z, Glazer PM, Herzon SB. The cytotoxicity of (-)-lomaiviticin A arises from induction of double-strand breaks in DNA. Nat Chem. 2014 Jun;6(6):504-10. doi: 10.1038/nchem.1944. Epub 2014 May 11. PubMed PMID: 24848236; PubMed Central PMCID: PMC4090708.9: Woo CM, Gholap SL, Herzon SB. Insights into lomaiviticin biosynthesis. Isolation and structure elucidation of (-)-homoseongomycin. J Nat Prod. 2013 Jul 26;76(7):1238-41. doi: 10.1021/np400355h. Epub 2013 Jun 26. PubMed PMID: 23803003.10: Zeng W, Eric Ballard T, Tkachenko AG, Burns VA, Feldheim DL, Melander C. Mimicking the biological activity of diazobenzo[b]fluorene natural products with electronically tuned diazofluorene analogs. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5148-51. Epub 2006 Jul 25. PubMed PMID: 16870443.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开